Table 2.

Clinical characteristics of 3 cycles

Cycle number	Date/Menstrual cycle	Medicine	Follicles of right ovary (mm(N))	Follicles of left ovary (mm(N))	Total Number of oocyte retrieved	Stage of Oocyte (N) after 24–36 h of culture in vitro
1					23	MI(22) + GV(1)
	2017.10.25/D18	GnRHa (mg):0.9
	2017.11.8/D5	rFSH(U): 150*5d	2*2(3)	2*2(4)
	2017.11.13/D10	rFSH(U): 150*4d	8*8(3),6*6(3)	10*9(2),8*7(1),7*5(3)
	2017.11.17/D14	rFSH(U): 150*3d	15*14(1),14*14(1),12*11(4)	15*15(1),15*13(2),16*12(1), 14*14(2),14*10(1),12*12(2)
	2017.11.20/D17	rHCG (ug): 250	21*21(1)	22*19(1),21*20(2),19*17(2), 19*16(2),18*17(1)
2					21	MI(12) + GV(2)+ + degenerate oocytes (7)
	2018.3.19/D3	HMG(U): 225*5d Clomiphene citrate (mg): 100*5d	5–6(3–6)	6–7(3–6)
	2018.3.24/D8	HMG(U): 225 Clomiphene citrate (mg): 100	16*13(1),14*13(1),13*12(1)	15*11(2)
	2018.3.25/D9	HMG(U): 225*2d Clomiphene citrate (mg): 100*2d Ganirelix (mg): 0.25*2d
	2018.3.27/D11	HMG(U): 225 Ganirelix (mg): 0.25	23*21(1),20*17(1),18*15(2),17*17(2),17*15(2)	20*17(2),18*14(2),17*12(2)
	2018.3.28/D12	Ganirelix (mg): 0.25 HCG (IU):8000	22*22(1),21*20(1),20*20(3),19*19(2),18*18(2)	23*17(1),22*20(1),18*18(1), 17*17(1)
3					12	MI(7) + GV(3) + degenerate oocytes(2)
	2018.9.18/D3	HMG(U): 225*4d	3–4(6)	3–4(7)
	2018.9.22/D7	HMG(U): 225*2d	8*8(1),6*5(1),5*5(1),4*4(1),4*3(1)	10*7(1),9*9(1),9*7(1),8*8(1)
	2018.9.24/D9	HCG(U): 10000	13*12(1),8*8(2),7*7(1),5*5(4)	13*13(1),13*12(1),12*12(1), 11*11(1),10*10(2),9*9(1)

D Day number of menstrual cycle, d Days of continuous medication, N Number, rFSH recombinant follicle stimulating hormone (Gonal-F, merck Serono, Switzerland), rHCG recombinant human chorionic gonadotrophin (Ovidrel, merck Serono, Germany), HMG human menopausal gonadotropin (Lebaode, Livzon, Zhuhai), HCG human chorionic gonadotrophin (Livzon, Zhuhai), GnRHa (Diphereline, Ipsen, France), Ganirelix (Orgalutran, merck sharp organon, USA), Clomiphene citrate (Clomifene Citrate Tablets, Hengshan, shanghai)